07:00 , Oct 6, 2008 |  BioCentury  |  Product Development

Designs on NS5b

The HCV polymerase non-structural protein 5b has been known for many years, but to date no company has successfully targeted it because of toxicology issues or lack of potency. Anadys Pharmaceuticals Inc. believes its structure-based...
07:00 , Sep 24, 2007 |  BioCentury  |  Strategy

Ship, captain and crew

Ardea Biosciences Inc. believes that its HIV drug candidate, RDEA806 , will have a better safety profile, fewer drug-drug interactions and greater activity against drug-resistant viral strains than approved and upcoming products in the NNRTI...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

Scale was elusive

MedImmune Inc. is going away in what can only be called a blaze of glory - a $15.6 billion takeout by AstraZeneca plc . The deal price is about a 53% premium to MEDI's valuation...
07:00 , Aug 8, 2005 |  BC Week In Review  |  Clinical News

Thymitaq nolatrexed: Phase III data

In the open-label, international Phase III ETHECC trial in 446 patients, Thymitaq missed the primary endpoint of survival benefit vs. doxorubicin. Additional data were not disclosed. Thymitaq, which has Fast Track and Orphan designations in...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Thymitaq nolatrexed: Completed Phase III enrollment

Eximias completed enrollment of 446 patients in the open-label, international Phase III ETHECC trial. Thymitaq, which has Fast Track and Orphan designations, was licensed from Agouron Pharmaceuticals Inc. (La Jolla, Calif.), a subsidiary of PFE....
02:08 , Apr 20, 2005 |  BC Extra  |  Clinical News

Eximias enrolls Thymitaq Phase III

Eximias (Berwyn, Penn.) completed enrollment of 446 patients in the open-label, international, Phase III ETHECC trial of Thymitaq nolatrexed (formerly AG337) to treat unresectable hepatocellular carcinoma (HCC). The primary endpoint is survival. Secondary endpoints include...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Company News

OncoGenex Technologies board of directors update

OncoGenex Technologies Inc. , Vancouver, B.C.   Business: Cancer   Appointed: Neil Clendeninn, former head of the clinical affairs group at Pfizer Inc. subsidiary Agouron Pharmaceuticals Inc.  ...
08:00 , Feb 2, 2004 |  BC Week In Review  |  Clinical News

Thymitaq nolatrexed: Phase III

Eximias said an independent data safety monitoring board (DSMB) unanimously recommended that the international Phase III (ETHECC) liver cancer trial continue. Eximias said the DSMB reviewed safety data from 306 patients from the ongoing trial....
08:00 , Nov 3, 2003 |  BC Week In Review  |  Company News

Chiron, Pfizer deal

CHIR non-exclusively licensed to PFE rights to research, develop and commercialize therapeutics against certain hepatitis C virus (HCV) targets. Financial terms were not disclosed. As part of the deal, CHIR withdrew litigation filed in 1998...
08:00 , Oct 28, 2003 |  BC Extra  |  Company News

Chiron, Pfizer HCV deal

CHIR non-exclusively licensed to PFE rights to research, develop and commercialize therapeutics against certain hepatitis C virus (HCV) targets. Financials were not disclosed As part of the deal, the companies also settled litigation involving Agouron...